Herpes zoster ophthalmicus (HZO) secondary to platelet-rich plasma (PRP) therapy - A case report.
Abstract
Androgenetic alopecia (AGA) is a common and benign cause of chronic hair loss that affects both males and females. Platelet-rich plasma (PRP) is a safe and minimally invasive technique with promising outcomes in patients with AGA, alongside other therapeutics use. The currently available data in the literature assures that the rate of side effects is low but includes infection and localized reaction (Stevens and Khetarpal, Feb. 2019) [1]. This article describes a case of herpes zoster ophthalmicus (HZO) following PRP treatment for androgenic alopecia, while shedding light on the importance of respecting the guidelines when injecting PRP therapy to ensure a safe outcome with no complications.
Кратко
A case of herpes zoster ophthalmicus is described following PRP treatment for androgenic alopecia, while shedding light on the importance of respecting the guidelines when injecting PRP therapy to ensure a safe outcome with no complications.
Used In Evidence Reviews
Similar Papers
Journal of cosmetic dermatology · 2021
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
Stem cells translational medicine · 2015
The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial.
Clinical reviews in allergy & immunology · 2021
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
Cells · 2019
Advances in Regenerative Stem Cell Therapy in Androgenic Alopecia and Hair Loss: Wnt pathway, Growth-Factor, and Mesenchymal Stem Cell Signaling Impact Analysis on Cell Growth and Hair Follicle Development.
The British journal of dermatology · 2013
A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2018